Stock C4X VALERIO THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Valerio Therapeutics BOERSE MUENCHEN

Equities

C4X

FR0010095596

Pharmaceuticals

Market Closed - BOERSE MUENCHEN
Other stock markets
 03:43:07 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.1018 EUR -.--% Intraday chart for Valerio Therapeutics +0.20% -32.81%
May. 22 Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial CI
Apr. 30 Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 44.31 32.42 52.01 38.52 15.64 25.42
Enterprise Value (EV) 1 40.1 35.29 43.74 30.57 11.19 29.61
P/E ratio -4.84 x -1 x 66.7 x -6 x -0.76 x -1.1 x
Yield - - - - - -
Capitalization / Revenue 7.23 x 7.56 x 29.3 x 9.48 x 10.8 x 14.1 x
EV / Revenue 6.54 x 8.23 x 24.6 x 7.53 x 7.75 x 16.4 x
EV / EBITDA -11.8 x -3.69 x -5.69 x -5.52 x -0.66 x -1.57 x
EV / FCF -7.11 x -8.03 x -4.87 x -4.16 x -3.83 x -3.01 x
FCF Yield -14.1% -12.5% -20.5% -24.1% -26.1% -33.2%
Price to Book 1.02 x 1.97 x 1.79 x 1.17 x 0.7 x 1.72 x
Nbr of stocks (in thousands) 50,815 58,407 77,977 91,722 111,059 154,077
Reference price 2 0.8720 0.5550 0.6670 0.4200 0.1408 0.1650
Announcement Date 4/9/19 4/27/20 4/23/21 4/28/22 4/29/23 5/2/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 6.127 4.289 1.776 4.062 1.443 1.8
EBITDA 1 -3.385 -9.564 -7.69 -5.535 -17.04 -18.92
EBIT 1 -3.527 -9.795 -7.814 -5.582 -17.11 -19.05
Operating Margin -57.56% -228.37% -439.98% -137.42% -1,185.93% -1,058.5%
Earnings before Tax (EBT) 1 -11.16 -36.05 1.846 -5.837 -19.28 -20.33
Net income 1 -9.399 -33.73 1.089 -5.937 -19.56 -20.34
Net margin -153.4% -786.38% 61.32% -146.16% -1,355.65% -1,130.22%
EPS 2 -0.1800 -0.5531 0.0100 -0.0700 -0.1850 -0.1505
Free Cash Flow 1 -5.636 -4.395 -8.974 -7.357 -2.919 -9.833
FCF margin -91.99% -102.47% -505.3% -181.11% -202.27% -546.3%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/9/19 4/27/20 4/23/21 4/28/22 4/29/23 5/2/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 2.87 - - - 4.18
Net Cash position 1 4.21 - 8.27 7.95 4.45 -
Leverage (Debt/EBITDA) - -0.3005 x - - - -0.2212 x
Free Cash Flow 1 -5.64 -4.4 -8.97 -7.36 -2.92 -9.83
ROE (net income / shareholders' equity) -19.7% -108% 4.71% -19.2% -70.9% -110%
ROA (Net income/ Total Assets) -3.12% -12.1% -11.6% -7.01% -22.2% -30.4%
Assets 1 301.3 277.9 -9.38 84.72 87.93 66.94
Book Value Per Share 2 0.8500 0.2800 0.3700 0.3600 0.2000 0.1000
Cash Flow per Share 2 0.2100 0.0900 0.1900 0.2000 0.1300 0.0400
Capex 1 0.05 0.03 0.12 0.14 0.49 0.18
Capex / Sales 0.73% 0.61% 6.7% 3.42% 33.82% 10.17%
Announcement Date 4/9/19 4/27/20 4/23/21 4/28/22 4/29/23 5/2/24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.108 EUR
Average target price
1.2 EUR
Spread / Average Target
+1,011.11%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 734B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 591B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 315B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 276B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 238B
NOVARTIS AG Stock Novartis AG
+9.78% 206B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 204B
AMGEN INC. Stock Amgen Inc.
+6.17% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ALVIO Stock
  4. C4X Stock
  5. Financials Valerio Therapeutics